Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 3/20 | 0.37 |
| ▸ | TACR1 | P25103 | 3/20 | 0.37 |
| ▸ | TACR3 | P29371 | 3/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | PTGFR | P43088 | 15/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4025552 | 0.91 | TACR2 (0.45) | TACR2TACR1TACR3EGLN2EGLN1 | |
| SCHEMBL4025558 | 0.91 | TACR2 (0.45) | TACR2TACR1TACR3EGLN2EGLN1 | |
| SCHEMBL14484758 | 0.89 | TACR2 (0.39) | TACR2TACR1TACR3PTGFR | |
| SCHEMBL14485288 | 0.88 | TACR2 (0.38) | TACR2TACR1TACR3EGLN2EGLN1 | |
| SCHEMBL6603926 | 0.88 | TACR2 (0.39) | TACR2TACR1TACR3PTGFRTBXA2R | |
| SCHEMBL14144503 | 0.87 | TACR2 (0.41) | TACR2TACR1TACR3EGLN2EGLN1 | |
| SCHEMBL14484786 | 0.86 | TACR2 (0.37) | TACR2TACR1TACR3PTGFRP2RX7 | |
| SCHEMBL14485492 | 0.86 | TACR2 (0.36) | TACR2TACR1TACR3PTGFR | |
| SCHEMBL14484775 | 0.85 | TACR2 (0.36) | TACR2TACR1TACR3PTGFR | |
| SCHEMBL14485552 | 0.84 | TACR2 (0.38) | TACR2TACR1TACR3PTGFRP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235541-B2 | Neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| US-20070021406-A1 | New neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| EP-1119551-B1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| EP-1433783-A2 | Naphthalenecarboxamides as tachykinin receptor antagonists | AstraZeneca AB (SE) | 2004-06-30 | — | — | EP | disclosed |
| EP-1119551-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000020389-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021406-A1 | New neurokinin antagonists for use as medicaments | NPSR1, HRH4, OPRL1 | TACR2 27/4885TACR1 12/4885TACR3 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.